AXT INC Reports Significant 2025 Revenue & Profit Decline Amidst Escalating Trade War, Secures $93.9M in Public Offering

summarizeSummary

AXT INC reported a sharp decline in 2025 revenue and gross profit, heavily impacted by US-China trade restrictions, but secured $93.9 million in a public offering to fund operations and InP capacity expansion.

check_boxKey Events

• Significant Financial Decline in 2025

  Revenue decreased 11.1% to $88.3 million, gross profit plummeted 52.8% to $11.2 million (12.7% gross margin), and net loss widened to $23.2 million for the year ended December 31, 2025.

• Severe Impact from US-China Trade Restrictions

  North American revenue fell 77.5% in 2025, now representing only 2% of total revenue, following China's February 2025 export controls on InP substrates and US tariffs increasing to 70% by March 2025. The timing for US export permits for InP remains uncertain.

• Successful Public Offering Boosts Liquidity

  The company completed a public offering in December 2025, raising $93.9 million in net proceeds, significantly increasing cash and equivalents to $128.4 million. Funds are earmarked for InP capacity expansion and general corporate purposes.

• Tongmei STAR Market IPO Remains Pending

  The IPO application for its Chinese subsidiary, Tongmei, is still under review by Chinese authorities, with investors holding a $49 million redemption right if the IPO is not completed.

auto_awesomeAnalysis

AXT INC's 2025 annual report reveals a challenging financial year marked by substantial declines in revenue and profitability, primarily driven by escalating US-China trade tensions. The company experienced a significant drop in North American sales due to new Chinese export controls on indium phosphide (InP) substrates and increased US tariffs. To bolster its financial position, AXT successfully completed a public offering, raising $93.9 million in net proceeds, which is crucial for liquidity and planned InP manufacturing expansion. However, the ongoing uncertainty surrounding trade restrictions and the pending IPO of its Chinese subsidiary, Tongmei, continue to pose material risks. The company also faces ongoing shareholder litigation, adding to operational complexities.